I think the tie up with Promega, the move into Therapeutics, and the exosome space in general will see this company substantially re-rated this year.
Sure, a capital raise is likely.....and knowing David Williams he'd probably like to increase his exposure....but even with that occurring, the stock could easily reach a $200mln mkt cap this year.
If you're waiting for the cap raise, you may miss the ride.
IIQ General Discussion, page-218
Add IIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
56.5¢ |
Change
0.010(1.80%) |
Mkt cap ! $50.61M | |||
| Open | High | Low | Value | Volume |
| 55.0¢ | 56.5¢ | 54.0¢ | $124.9K | 227.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10000 | 56.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 57.5¢ | 70 | 1 |
View Market Depth
| Last trade - 14.33pm 06/06/2024 (20 minute delay) ? |
|
|||||
|
Last
56.0¢ |
Change
0.010 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 55.0¢ | 56.0¢ | 54.5¢ | 14059 | ||
| Last updated 14.17pm 06/06/2024 ? | |||||
| IIQ (ASX) Chart |